# US 2021/0275586 A1 · Use of a car cell having crosslinked disulfide bridge on antigen recognizing moiety for targetting cancer cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0275586 A1
- Document ID: US20210275586A1
- Status: Published application
- Kind: A1
- Application number: 17/194,424
- Filed: 2021-03-08
- Published: 2021-09-09
- Earliest claimed: 2020-03-09
- Assignees: Miltenyi Biotec GmbH
- Applicants: Miltenyi Biotec B.V. & Co. KG
- Inventors: Joerg Mittelstaet; Jonathan Fauerbach; Christian Dose; Andrew Kaiser
- Web page: https://patentgrep.com/patent/US20210275586A1

## CPC

- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- C07K 16/2803: {against the immunoglobulin superfamily}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/4211: {CD19 or B4}
- A61K 40/4221: {CD20}
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 16/2887: {against CD20}
- A61K 2239/24: Dimerizable CARs; CARs with adapter
- A61K 2239/31: characterized by the route of administration
- A61K 2239/38: characterised by the dose, timing or administration schedule
- A61K 2239/48: Blood cells, e.g. leukemia or lymphoma
- C07K 2317/55: Fab or Fab'
- C07K 2319/03: containing a transmembrane segment
- C07K 2319/40: containing a tag for immunodetection, or an epitope for immunisation
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention is directed to the use or a method of using of a cell expressing a chimeric antigen recognition structure (CAR) bound to an adapter molecule, wherein: i) the CAR structure comprises a) an antigen binding domain specific for the tag of the adapter molecule, b) a transmembrane domain c) an intracellular domain wherein the ii) the adapter molecule comprises a) a tag which is specific for the antigen binding domain of the CAR structure b) a polypeptide comprising an antigen recognizing domain specific for an antigen expressed on the target cell, wherein the polypeptide comprises a heavy chain and a light chain connected by a sulphur atom-linker-sulphur atom bridge and wherein the linker is covalently bound to a single tag for targeting target cells, especially human tumor cells.

## Claims

### Claim 1

Use of a cell expressing a chimeric antigen recognition structure (CAR) non-covalently bound to an adapter molecule, wherein:
i) the CAR structure comprises
a) an antigen binding domain specific for the tag of the adapter molecule,
b) a transmembrane domain
c) an intracellular domain
wherein the
ii) the adapter molecule comprises
a) a tag which is specific for the antigen binding domain of the CAR structure
b) a polypeptide comprising an antigen recognizing domain specific for an antigen expressed on the target cell, wherein the polypeptide comprises a heavy chain and a light chain connected by a sulphur atom-linker-sulphur atom bridge and wherein the linker is covalently bound to a single tag
for targeting target cells.

### Claim 2 (depends on 1)

Use according to claim 1 characterized in that the target cells are tumor cells.

### Claim 3 (depends on 1)

Use according to claim 1 characterized in that the target cells originate from a solid tumor.

### Claim 4 (depends on 1)

Use according to claim 1 characterized in that the target cells originate from tumor microenvironment (TME) of a solid tumor.

### Claim 5 (depends on 1)

Use according to claim 1 characterized in that the target cells originate from auto-immune disease.

### Claim 6 (depends on 1)

Use according to claim 1 characterized in that the adapter molecules bind and are specific for soluble antigens.

### Claim 7 (depends on 1)

Use according to claim 1, characterized in that the tag is selected from the group consisting of amino acids, peptides, polypeptides, proteins, creatinine, biotin, biocytin, thiamin, fluorochromes, lipids, hormones, other vitamins, carbohydrates.

### Claim 8 (depends on 1)

Use according to claim 1, characterized in that the adapter molecule was generated by reducing the disulfide bond between the heavy chain and a light chain of a polypeptide and subsequent reaction with the linker wherein the linker is a molecule consisting of the family of equilibrium transfer alkylation reagents, or the family of dihalogenated maleimides reagents or the family of pyridazedione reagents.

### Claim 9 (depends on 1)

Use according to claim 1, characterized in that the cell expressing a chimeric antigen recognition structure (CAR) is a T-Cell, B-cell, NK cell, dendritic cell, tumor infiltrating lymphocyte or macrophage.

### Claim 10 (depends on 1)

Use according to claim 1, characterized in that the cell expressing a chimeric antigen recognition structure (CAR) is a T cell; the antigen binding domain specific for the tag is anti-biotin; the tag is biotin; and the linker is derived from the family of equilibrium transfer alkylation reagents, and the polypeptide is an antibody fragment (Fab molecule).

### Claim 11 (depends on 1)

Use according to claim 1, characterized in that the cell expressing a chimeric antigen recognition structure (CAR) is a T cell; the antigen binding domain specific for the tag is anti-thiamin; the tag is thiamin; and the linker is derived from the family of equilibrium transfer alkylation reagents, and the polypeptide is an antibody fragment (Fab molecule)
